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Impact of Coronary Ostial lesions for Clinical Outcomes After Percutaneous
Coronary Intervention
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Background: It is well known that right coronary artery ostium (RCA-os) is
anatomically different from unprotected left main ostium (ULM-os). However,
there is a little data regarding the comparison of clinical outcome of percutaneous
coronary intervention (PCI) between RCA-os and ULM-os. Therefore, to clarify
the difference of impact between each ostial lesion, clinical outcomes following
PCI between patients who were treated for RCA-os and those for ULM-os were
compared.
Methods: Between January 2004 and December 2011, 1021 consecutive patients
treated for ostial lesions were included in this analysis. After exclusion of patients
treated for both RCA-os and ULM-os, 189 patients with RCA-os and 602 patients
with ULM were enrolled. The study endpoints were major adverse cardiac event
(MACE) during follow up period (median Follow-up 37.4 months) which deﬁned as
target lesion revascularization (TLR), all cause death and MI. Furthermore, the
composite of MACE were evaluated. TLR for ULM-os was considered as treatments
for restenosis of ULM-os itself.
Results: Baseline and procedural characteristics were not signiﬁcantly different be-
tween the 2 groups. The occurrence of MACE was signiﬁcantly higher in the RCA-os
than the ULM-os due to the high rate of TLR (p< 0.001, HR¼6.349, 95%CI 3.980-
10.129). On the contrary, all cause death was signiﬁcantly higher in the ULM-os than
the RCA-os (p¼0.004, HR¼5.627, 95%CI 1.748-18.107).
Conclusions: The TLR rate was signiﬁcantly higher in patients with RCA-os than in
those with ULM-os, while all cause mortality was signiﬁcantly higher in ULM-os
compared to RCAos.
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Background: Treatment of the aorta-ostial (AO) region of the right coronary artery
(RCA) with bare metal stents and ﬁrst-generation drug-eluting stents (DES) has been
associated with a higher risk of target-lesion revascularization (TLR). The aim of the
present analysis was to assess the impact on clinical outcome of RCA ostial stent
coverage with second-generation DES.
Methods: We identiﬁed from the total of 1,391 TWENTE trial patients 321 (23%)
patients with single-vessel RCA treatment. The angiographic data of these patients
were categorized into stenting with AO stent coverage (AOC) versus stenting without
AO stent coverage. A patient was allocated to the AOC group, if any part of the stent
covered the AO region (i.e., within 3 mm of the aortic oriﬁce).
Results: The 67 (20.9%) patients with AOC showed more severe lesion calciﬁca-
tion than the 254 patients without AOC (31.3% vs. 12.6%; p< 0.01). In the AOC
group, there was a higher prevalence of hypercholesterolemia and family history of
coronary disease (75.4% vs. 61.6%, and 68.7% vs. 53.5%, respectively; p¼0.03).
During 2-year follow-up, patients in the AOC group had a higher incidence of TLR
(7.5% vs. 1.6%; p¼0.02). Following adjustment for confounders, AOC indepen-
dently predicted TLR with an adjusted hazard ratio of 4.1 (95%CI: 1.17-15.48;
p¼0.04).
Conclusions: Treatment of the AO region of the RCA with second-generation DES is
feasible, but our data suggest that stent coverage of the right AO segment remains a
predictor of TLR.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/CoDiabetes
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Outcomes with Coronary Artery Bypass Graft Surgery vs. Percutaneous
Coronary Intervention for Patients with Diabetes Mellitus - Can Newer
Generation Drug Eluting Stents Bridge the Gap?
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Background: Coronary artery bypass graft surgery (CABG) compared with percu-
taneous coronary intervention (PCI) reduces mortality in diabetics. However, prior
trials compared CABG with balloon angioplasty or older generation stents and it is not
known if the gap between CABG and PCI can be reduced by newer generation drug
eluting stents (DES).
Methods: PUBMED/EMBASE/CENTRAL, search for randomized trials comparing
mode of revascularization in patients with diabetes. Primary outcome was all-cause
mortality. Secondary outcomes were myocardial infarction (MI), repeat revasculari-
zation and stroke. Mixed treatment comparison analyses were performed using a
random effects Poisson regression model.
Results: Seventy-two randomized trials that enrolled 24,742 diabetic patients with a
total of 72,387 patient-years of follow-up satisﬁed our inclusion criteria. When
compared with CABG (reference RR¼ 1.0), PCI with BMS [RR¼1.32(1.01-1.78)],
PES [RR¼1.54 (1.14-2.03)] or SES [RR¼1.40 (1.08-1.88)] were each associated with
an increase in mortality. However, PCI with 2nd generation DES-CoCr EES [RR
¼1.12 (0.67-2.10)] or ZES-R [RR 1.15 (0.28-6.27)] were not associated with a sta-
tistically signiﬁcant increase in mortality. When compared with CABG, there was
excess repeat revascularization with PCI which progressively declined from POBA
(335% increase) to BMS (220% increase) to PES (82% increase) and to SES (47%
increase). However, for PCI with CoCr EES [RR ¼1.32 (0.75-2.24)] and ZES-R [RR
¼2.37 (0.97-5.80)], the excess repeat revascularization was not statistically signiﬁ-
cant, although the point estimate favored CABG. CABG was associated with
numerically higher stroke.
Conclusions: In patients with diabetes, evidence from indirect comparison show
similar mortality between CABG and PCI using 2nd generation DES. CABG was
associated with numerically excess stroke and PCI with 2nd generation DES with
numerically increased repeat revascularization. This hypothesis needs to be tested in
future trials.
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Background: The outcome of patients with diabetes mellitus (DM) after drug-eluting
stent (DES) implantation is worse than that of patients without DM. Pioglitazone (Pio)
decreases cardiovascular (CV) events via anti-atherosclerotic effects, as well as a
blood glucose-lowering effect in patients with DM. We reported that Pio signiﬁcantly
decreased CV events in Japanese patients with DM after DES implantation according
to 1-year follow-up results of the J-DESsERT trial.
Methods: This study aimed to evaluate the effect of Pio on CV events in Japanese
patients with DM after DES implantation based on 3-year follow-up results of the J-
DESsERT trial. In the J-DESsERT trail, a prospective multicenter randomized
controlled trial, 3533 patients were randomized 1:1 to coronary stenting with either a
sirolimus-eluting stent or a paclitaxel-eluting stent, and followed for 3 years. The
criteria of lesion length was  46 mm with vessel diameters from 2.5 to  3.75 mm.
Deﬁnitions for DM in this trial were (1) previous diagnosis of DM; (2) currently on
diabetic medication (oral hypoglycemic drugs or injection of insulin preparation); and
(3) HbA1c6.9%(NGSP) within 30 days before the procedure.
Results: The number of patients with DM was 1705 (48%) in this trial. Among
them, 357 patients had been medicated with Pio before percutaneous coronary
intervention. The rate of CV events (death, myocardial infarction, target vesselronary Lesions - Other B71
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comrevascularization and cerebral vascular accidents) 1 year after DES implantation in
the Pio-treated group was signiﬁcantly decreased (6.6%) compared with that with
other therapies in the group without Pio (12.0%, P< 0.01). The rate of CV events
3 years after DES implantation in the Pio-treated group was signiﬁcantly decreased
(10.6%) compared with that with other therapies in the group without Pio (19.1%,
P< 0.01).
Conclusions: Pioglitazone signiﬁcantly decreases CV events of Japanese patients
with DM after DES implantation according to 1-year and 3-year follow-up results.
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Background: Aim of the present study is to investigate 1-year clinical outcomes after
implantation of BVS vs. EES in all-comer diabetic patients, including those with
complex lesion characteristics.
Methods: Consecutive diabetic patients treated with BVS between May 2007 and
April 2014 and those treated with EES between December 2006 and August 2012 in
two Italian centers were included in this retrospective study. One-year clinical out-
comes of major adverse cardiac event (MACE: composite of all-cause mortality, any
myocardial infarction and target vessel revascularization) and target lesion revascu-
larization (TLR) were compared between the two groups.
Results: Forty eligible patients (65 lesions) treated with BVS, and 264 (356 lesions)
treated with EES were enrolled. Mean age (BVS: 62.81.9 vs. EES: 65.71.6,
p¼0.13) and male gender (92.5% vs. 82.2%, p¼0.11) were similar in both groups.
The use of insulin (32.5% vs. 30.7%), prevalence of chronic kidney disease (22.5% vs.
21.5%, p¼1.00) and ejection fraction (55.0 (IQR: 50.0-60.0) vs. 55.0 (50.0-60.0),
p¼0.48) were also similar. With regards to lesion characteristics, total stent length per
patient was higher in the BVS compared to the EES group (28mm (28-55) vs 23mm
(18-36), p< 0.001). At 1-year follow-up, MACE occurred in 17.9% patients in the
BVS group and 14.2% in the EES group (p¼0.36), whereas TLR occurred in 8.9% of
patients in the BVS and 7.2% in the EES group (p¼0.76). After 1:2 propensity
matching (40 BVS patients:80 EES patients), 1-year MACE was observed in 17.9% of
BVS patients vs 8.9% of EES (p¼0.077). TLR was 8.9% in the BVS group and 3.9%
in the EES group (p¼0.19). The major contribution to MACE were periprocedural
myocardial infarctions (pMI: CK-MB>5) (7.5% with BVS and 0% with EES). A
more aggressive predilatation and postdilation and the thicker stent struts of BVS may
explain the higher incidence of pMI.
Conclusions: BVS implantation in all comer diabetics, including those with complex
coronary lesions is feasible with acceptable 1-year outcomes when compared to EES.
The higher incidence of pMI warrants further investigation.
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Background: Diabetes mellitus is a risk factor for poor outcomes after PCI. The
newer-generation metallic drug-eluting stents (DES) have improved outcomes in non-
diabetics, but outcomes remain poor in diabetics. Bioresorbable scaffolds are novel
devices for coronary revascularization; however, long-term clinical outcomes of these
devices in diabetics have not been reported. Aim of this study was to evaluate 2-year
clinical outcomes in diabetic patients treated with everolimus-eluting bioresorbable
vascular scaffolds (BVS).
Methods:We compared outcomes in 142 diabetics and 434 non-diabetics treated with
BVS from Absorb Cohort B and Absorb EXTEND. Furthermore, BVS treated di-
abetics (n¼103) were compared with propensity matched diabetics (n¼175) treated
with metallic XIENCE everolimus-eluting stents (EES) from SPIRIT First, II, III and
IV studies. Patient-oriented composite endpoint (PoCE, including all death, all MI,
and all revascularizations), device-oriented composite endpoint (DoCE, including
cardiac death, target vessel MI, or target lesion revascularization) and scaffold/
stent thrombosis (deﬁnite and probable according to ARC) were assessed at 2-year
follow-up.B72 JACC VolResults: BVS treated diabetics had similar baseline characteristics as BVS treated
non-diabetics except for the presence of diabetes and hypertension. At 2-year follow-
up, there were no signiﬁcant differences in PoCE (diabetics 10.6% vs non-diabetics
12.9%, p¼0.46), DoCE (diabetics 4.2% vs non-diabetics 7.6%, p¼0.16) and scaffold
thrombosis (diabetics 0.7% vs non-diabetics 0.9%, p¼1.0) between the two groups.
BVS and EES treated diabetics were well-matched for demographic, clinical and
procedural characteristics, except for longer duration of DAPT in the BVS group.
PoCE (BVS 12.6% vs EES 10.9%, p¼0.66), DoCE (BVS 5.8% vs EES 5.7%,
p¼0.97) and scaffold/stent thrombosis (BVS 1.0% vs EES 0.6%, p¼1.0) were similar
in the diabetics treated with BVS or EES at 2-year follow-up.
Conclusions: Patient- and device-oriented outcomes in BVS treated patients were
independent of diabetic status, and were comparable to the outcomes observed with
EES. A prospective randomized clinical trial is warranted to determine the optimal
device for diabetic patients.
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Background: Diabetes is associated with diffuse coronary artery disease and worse
clinical outcome after stenting with metallic stents. Everolimus-eluting bioresorbable
vascular scaffolds (BVS, Abbott Vascular, Santa Clara, California, USA) represent a
new approach. This study aimed to evaluate feasibility and mid-term clinical outcome
after implantation of BVS in diabetics.
Methods: All patients with diabetes who had been treated with BVS in the vicinity of
our all-comers registry were included, irrespective of their clinical presentation. Target
parameters were target vessel failure (TVF), major adverse cardiac events (MACE)
including target lesion revascularization (TLR), cardiac death, myocardial infarction
and emergency coronary bypass graft surgery. Follow-up was performed by telephone
call and/ or ofﬁce visit.
Results: A total of 100 patients were included, of whom 15 % had a STEMI, 20 % a
NSTEMI, 13 % presented instable angina and 52 % stable angina. Median age was 67
(60-73) years, 29%were female, 97% suffered from hypertension. Of all patients, 36%
patients have an insulin-dependent diabetes, all other patients were treated with oral
antidiabetics or dietary. Median procedure time was 56.5 min (41 – 70), mean contrast
volume was 178.3 mL ( 92.3). A total of 105 bioresorbable vascular scaffolds were
implanted with a mean number of 1.4  0.8 per patient. There was no implantation
possible in two cases. Median follow-up duration was 175 (59 – 316) days. Three
scaffold thromboses occurred, of which two were most probably due to discontinuation
of dual antiplatelet therapy. One in-scaffold restenosis was noted. In summary the total
rates of TVF, TLR and MACE were 5.1, 4.1 and 8.0 %, respectively.
Conclusions: Since the experience with bioresorbable vascular scaffolds in speciﬁc
subsets is limited, this study conﬁrms safety of bioresorbable vascular scaffold im-
plantation in diabetics. Furthermore our results demonstrate satisfying mid-term
clinical outcome. DAPT seems to be extraordinary crucial to prevent scaffold
thrombosis. Nevertheless, long-term data is required for ﬁnal evaluation.
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Background: Percutaneous coronary intervention (PCI) of small vessels has been
associated with high risk of recurrent events, especially in patients with diabetes
mellitus (DM).
Methods: We examined outcomes of patients with small reference diameter (2.5
mm) vessels who underwent PCI using ResoluteTM zotarolimus-eluting stent (R-
ZES) in the pooled RESOLUTE program stratiﬁed by diabetic status. Target Lesion
Failure (TLF) was composite of death from cardiac causes, target vessel myocardial
infarction (TV-MI), and target lesion revascularization (TLR). The incidence of
clinical events was calculated using the Kaplan Meier method.
Results: Among 2721 patients with at least one small vessel lesion treated with R-
ZES, 233 patients had insulin dependent DM (IDDM), 724 patients had non-insulin
dependent diabetes mellitus (non-IDDM), and 1764 patients did not have diabetes (no-
DM). There were signiﬁcant differences in baseline characteristics, in particular
greater complexity with IDDM patients. At 3-years, TLR was similar in non-DM and
NIDDM, and was signiﬁcantly lower than in IDDM patients (Figure). Similarly, TLF
(9.7% vs. 11.1% vs. 21.8%, p< 0.001), CD/TV-MI (5.6% vs. 7.4% vs 11.8%,
p¼0.002), and ARC Deﬁnite/Probable ST (0.9% vs. 1.1% vs. 1.3%, p¼0.81), were
lower among non-DM and NIDDM patients.
Conclusions: Among patients undergoing PCI with small vessels in the pooled
RESOLUTE program, NIDDM and non-DM patients had similar 3-year outcomes,
which was lower than with IDDM. These outcomes demonstrate the long-term safety
and effectiveness of R-ZES in complex NIDDM and non-DM patients. Submitted on
behalf of the RESOLUTE Global Clinical Program64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Diabetes
